Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582028 | 0.93 | SCN9A (0.40) | PTK2SCN9AJAK2JAK1TYK2 | |
| SCHEMBL5581967 | 0.92 | CA1 (0.41) | SCN9APTGS2PTGS1JAK2JAK1 | |
| SCHEMBL5581820 | 0.89 | ADORA1 (0.43) | SCN9AJAK2JAK1CSNK2A2CSNK2B | |
| SCHEMBL5581770 | 0.87 | ADORA1 (0.40) | SCN9AJAK2JAK1CSNK2A2CSNK2B | |
| SCHEMBL5582212 | 0.86 | CSNK2A1 (0.49) | PTK2LRRK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5741142 | 0.86 | MAP4K4 (0.35) | PTK2SCN9AJAK2JAK1TYK2 | |
| SCHEMBL5581601 | 0.86 | MAP4K4 (0.36) | SCN9AJAK2JAK1CSNK2A2CSNK2B | |
| SCHEMBL5581976 | 0.86 | PDE4B (0.39) | SCN9ACSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5582071 | 0.84 | FYN (0.39) | SCN9AJAK2JAK1CSNK2A2CSNK2B | |
| SCHEMBL5582163 | 0.84 | PDE4B (0.42) | SCN9ACSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | PTK2 4482/4885SCN9A 1396/4885PTGS2 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.